Transforming Growth Factor Beta 1 (TGFb1)

TGF-B1; CED; DPD1; LAP; Camurati-Engelmann Disease; Latency-associated peptide

SPN	W589
HGNC	11766
MGI	98725
PubMed	10973241
RGD	69051
UniProt	P01137
Wiki	TGF_beta_1

TGF-β is capable of producing a variety of effects and virtually all cell types respond to this factor in some way. The inappropriate presence of active TGF-β1 has been implicated in a variety of pathological conditions Because of the necessity for regulating its activity tightly, TGF-β is secreted by cells in the form of an inactive complex. This complex consists of TGF-β1 associated non-covalently with a protein designated the latency associated peptide (LAP).

TGF-β1 and LAP represent components of a pro-peptide that is cleaved in a post-golgi compartment prior to secretion. LAP and TGF-β1 each consist of a disulfide-linked homodimer and the association of these two components renders TGF-β1 inactive and inaccessible to anti-TGF-β antibodies.

Reference

"Intron-exon structure of the human transforming growth factor-beta precursor gene."
Nucleic Acids Res. 15:3188-3189(1987) [PubMed] [Europe PMC] [Abstract]

"Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells."
Nature 316:701-705(1985) [PubMed] [Europe PMC] [Abstract]

"Complete sequencing and characterization of 21,243 full-length human cDNAs."
Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]

"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]

"Cloning and expression of the gene for human transforming growth factor-beta in Escherichia coli."
Tumor Res. 22:41-55(1987)

"Recombinant human transforming growth factor-beta 1: expression by Chinese hamster ovary cells, isolation, and characterization."
Protein Expr. Purif. 4:130-140(1993) [PubMed] [Europe PMC] [Abstract]

"Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines."
J. Biol. Chem. 260:2636-2645(1985) [PubMed] [Europe PMC] [Abstract]

"Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization."
J. Biol. Chem. 263:6407-6415(1988) [PubMed] [Europe PMC] [Abstract]

"Latent transforming growth factor-beta: structural features and mechanisms of activation."
Kidney Int. 51:1376-1382(1997) [PubMed] [Europe PMC] [Abstract]

"Dermatopontin interacts with transforming growth factor beta and enhances its biological activity."
Biochem. J. 337:537-541(1999) [PubMed] [Europe PMC] [Abstract]

"Differential gene expression of cultured human osteoblasts."
J. Cell. Biochem. 83:547-553(2001) [PubMed] [Europe PMC] [Abstract]

"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."
J. Proteome Res. 4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]

"Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes."
FASEB J. 20:1525-1527(2006) [PubMed] [Europe PMC] [Abstract]

"Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach."
Mol. Cell. Proteomics 5:226-233(2006) [PubMed] [Europe PMC] [Abstract]

"Mechanisms for asporin function and regulation in articular cartilage."
J. Biol. Chem. 282:32185-32192(2007) [PubMed] [Europe PMC] [Abstract]

"Initial characterization of the human central proteome."
BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]

"Transforming growth factor beta 1: NMR signal assignments of the recombinant protein expressed and isotopically enriched using Chinese hamster ovary cells."
Biochemistry 32:1152-1163(1993) [PubMed] [Europe PMC] [Abstract]

"Transforming growth factor beta 1: secondary structure as determined by heteronuclear magnetic resonance spectroscopy."
Biochemistry 32:1164-1171(1993) [PubMed] [Europe PMC] [Abstract]

"Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2."
Biochemistry 35:8517-8534(1996) [PubMed] [Europe PMC] [Abstract]

"Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women."
J. Bone Miner. Res. 13:1569-1576(1998) [PubMed] [Europe PMC] [Abstract]

"Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease."
Nat. Genet. 26:19-20(2000) [PubMed] [Europe PMC] [Abstract]

"Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease."
Nat. Genet. 26:273-275(2000) [PubMed] [Europe PMC] [Abstract]

"A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway."
J. Hum. Genet. 47:478-483(2002) [PubMed] [Europe PMC] [Abstract]

"Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein."
J. Biol. Chem. 278:7718-7724(2003) [PubMed] [Europe PMC] [Abstract]

"A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro."
J. Clin. Endocrinol. Metab. 88:3321-3326(2003) [PubMed] [Europe PMC] [Abstract]

"TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations."
Am. J. Med. Genet. 127A:104-107(2004) [PubMed] [Europe PMC] [Abstract]